Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study

Purpose: To compare the incidence and severity of acute and chronic hematologic toxicity (HT) in patients treated with three-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) for curative treatment of cervical cancer and to ascertain the dosimetric parameters of two techniques associated with acute and chronic HT. Materials and Methods: A total of 127 patients with cervical cancer receiving concomitant pelvic radiotherapy (RT) and cisplatin were evaluated. Pelvic bone marrow (BM) was contoured for each patient and divided into five subregions: lumbosacrum (LS), ilium (IL), lower pelvis (LP), pelvis (P), and whole pelvis (WP). The volume of each BM region receiving 10,20,30, and 40 Gy was calculated (V10, -V20, -V30, and -V40). The lowest level of hemoglobin, leukocyte, neutrophil, and platelet counts were obtained during chemoradiotherapy and six months after RT. The nadir values were graded according to Common Terminology Criteria for Adverse Events (version 3.0). Results: Grade 2 or greater acute anemia, leukopenia, neutropenia, thrombocytopenia was observed in 2%, 41.5%, 12% ,and 0% in 3DCRT group and in 27%, 53%, 24.5%, and 4.5% in IMRT group, respectively. Grade 2 or greater chronic anemia, leukopenia, neutropenia, and thrombo-cytopenia was observed in 11%, 10%, 6%, and 0% in 3DCRT group and in 11%, 9%, 4.5%, and 0% in IMRT group, respectively. LS-V30,40; IL-V10,20,30,40; LP-V10,20,40; P-V10,20,30,40, and TP-V10,20,30,40 were significantly reduced with IMRT planning compared to 3DCRT planning. Logistic regression analysis of potential predictors showed that none of the dosimetric parameters were significant for predicting acute and chronic HT. Conclusion: The present findings showed that IMRT planning reduced irradiated BM volumes compared to 3DCRT planning. However, no difference between the two techniques was observed in terms of acute and chronic HT. Further studies are needed to confirm these results.

Hematologic toxicity; Cervical cancer; Radiotherapy; Chemotherapy.

[1] Peters W.A., Liu P.Y., Barrett R.J..2nd, Stock R.J., Monk B.J., Berek J. S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[2] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. 3rd, et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[3] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R. E., et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation or high-risk cervical cancer”. N. Engl. J. Med., 1999, 340, 1137.

[4] Brixey C.J., Roeske J.C., Lujan A.E., Yamada S.D., Rotmensch J., Mundt A.J.: “Impact of intensity modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies”. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54, 1388.

[5] Sood B.M., Timmins P.F., Gorla G.R., Garg M., Anderson P.S., Vikram B., Goldberg G.L.: “Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer”. Int. J. Gynecol. Cancer, 2002, 12, 459.

[6] Lanciano R.M., Pajak T.F., Martz K., Hanks G.E.: “The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A Patterns of Care study”. Int. J. Radiat. Oncol. Biol. Phys., 1993, 25, 391.

[7] Ellis R.E.: “The distribution of active bone marrow in the adult”. Phys. Med. Biol., 1961, 5, 255.

[8] Mauch P., Constine L., Greenberger J., Knospe W., Sullivan J., Liesveld J.L., Deeg H.J.: “Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 31, 1319.

[9] Tubiana M., Carde P., Frindel E.: “Ways of minimizing hematopoietic damage induced by radiation and cytostatic drugs-the possible role of inhibitors”. Radiother Oncol., 1993, 29, 1.

[10] Verschraegen C.F., Levy T., Kudelka A.P. Llerena E., Ende K., Freedman R.S., et al.: “Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix”. J. Clin. Oncol., 1997, 15, 625.

[11] Look K.Y., Blessing J.A., Levenback C., Kohler M., Chafe W., Roman L.D.: “A phase II trial of CPT-11 in recurrent squamous car-cinoma of the cervix: A Gynecologic Oncology Group study”. Gynecol. Oncol., 1998, 70, 334.

[12] Mell L.K., Kochanski J.D., Roeske J.C. Haslam J.J., Mehta N., Yamada S.D., et al.: “Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66, 1356. Epub 2006 Jun 6.

[13] Mell L.K., Tiryaki H., Ahn K.-Y., Mundt A.J., Roeske J.C., Aydogan B.: “Dosimetric comparison of bone marrow sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71, 1504.

[14] Albuquerque K., Giangreco D., Morrison C., Siddiqui M., Sinacore J., Potkul R., Roeske J.: “Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for Bone Marrow-Sparing IMRT”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79, 1043. doi: 10.1016/j.ijrobp.2009.12.025. Epub 2010 May 12.

[15] Lujan A.E., Roeske J.C., Mundt A.J.: “Intensity- modulated radiation therapy as a means of reducing dose to bone marrow in gynecological patients receiving whole pelvic radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 516.

[16] Baumann M., Bentzen S.M.: “Clinical manifestations of normal-tissue damage”. In: Steel G.G., editor. Basic Clinical Radiobiology 3rd ed. New York: Arnold, 2002, 105.

[17] Vogler J.B. 3rd, Murphy W.A.: “Bone marrow imaging”. Radiology, 1988, 168, 679.

[18] Rose B.S., Liang Y., Lau S.K. Jensen L.G., Yashar C.M., Hoh C.K., Mell L.K.: “Correlation between radiation dose to 18F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 83, 1185. doi: 10.1016/j.ijrobp.2011.09.048. Epub 2012 Jan 21.